7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives

      editorial

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This article, co-authored by a patient affected by bilateral, recurrent, atypical optic neuritis, and clinicians, discusses the mental burden of living with uncertainty and the possibility of further sight loss, along with the side effects of treatment. The patient shares some of the challenges, coping strategies, and the value they found in creating and participating in a patient support group. The physicians consider whether current clinical measures adequately capture the outcomes that matter to patients and discuss the role for patient-reported outcome measures (PROMs). We identify technological advances that are lowering traditional barriers to the use of PROMs in research and routine clinical care and look towards new PROM instruments enhancing shared patient-physician care in the future.

          Plain Language Summary

          In this patient-physician perspective article, we share the story of a patient affected by an autoimmune disease that attacks the nerves connecting the eyes and the brain and reflect back physicians’ perspectives on the disease and the patient’s experience of it. In a compelling account, we gain some understanding of what it might be like to live with the fear of unpredictable episodes of sudden, recurrent sight loss and the important impacts that this has on a patient’s life and mental wellbeing. We recognize that the outcome metrics that physicians usually focus on, such as measurement of vision and imaging of the optic nerve, do not fully capture the outcomes that most matter to the patient. We explore patient-reported outcome measures that go some way towards bridging this gap. Finally, we consider the technological advances that will make more comprehensive capture of the patient experience a reality in future clinical practice and research, supporting both patients and physicians to optimize shared care.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: not found
          • Article: not found

          Clinical presentation and prognosis in MOG-antibody disease: a UK study

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice

            This review article considers the rising demand for patient-reported outcome measures (PROMs) in modern ophthalmic research and clinical practice. We review what PROMs are, how they are developed and chosen for use, and how their quality can be critically appraised. We outline the progress made to develop PROMs in each clinical subspecialty. We highlight recent examples of the use of PROMs as secondary outcome measures in randomized controlled clinical trials and consider the impact they have had. With increasing interest in using PROMs as primary outcome measures, particularly where interventions have been found to be of equivalent efficacy by traditional outcome metrics, we highlight the importance of instrument precision in permitting smaller sample sizes to be recruited. Our review finds that while there has been considerable progress in PROM development, particularly in cataract, glaucoma, medical retina, and low vision, there is a paucity of useful tools for less common ophthalmic conditions. Development and validation of item banks, administered using computer adaptive testing, has been proposed as a solution to overcome many of the traditional limitations of PROMs, but further work will be needed to examine their acceptability to patients, clinicians, and investigators.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25.

              To determine whether a 10-Item Neuro-Ophthalmic Supplement increases the capacity of the 25-Item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) to capture self-reported visual dysfunction in patients with neuro-ophthalmologic disorders. A cross-sectional survey to examine the characteristics of a 10-Item Neuro-Ophthalmic Supplement to the 25-Item NEI-VFQ-25 in a cohort of patients with neuro-ophthalmologic disorders. The 10-Item Neuro-Ophthalmic Supplement was designed previously by our research group by survey and focus-group methods. In the present study, the NEI-VFQ-25 and 10-Item Supplement were administered concurrently to patients and disease-free control subjects. High-contrast visual acuities with patient usual distance correction were measured with the use of Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Diagnoses for patients (n = 215) included optic neuritis, multiple sclerosis, idiopathic intracranial hypertension, ischemic optic neuropathy, stroke, ocular myasthenia gravis, ocular motor palsies, and thyroid eye disease. Scores for the 10-Item Supplement had a significant capacity to distinguish patients vs disease-free control subjects that was independent of the NEI-VFQ-25 composite score (odds ratio in favor of patient vs control status for 10-point worsening in Supplement scores: 2.7 [95% confidence interval [CI], 1.6, 4.6]; P or= .001, linear regression). Supplement items and composite scores demonstrated appropriate degrees of internal consistency reliability. The 10-Item Neuro-Ophthalmic Supplement demonstrates a capacity to capture self-reported visual dysfunction beyond that of the NEI-VFQ-25 alone, which supports validity for this new scale. The use of the 10-Item Supplement in clinical trials and epidemiologic studies will examine its capacity to demonstrate treatment effects in longitudinal cohorts.
                Bookmark

                Author and article information

                Contributors
                tasaneebraithwaite@gmail.com
                Journal
                Ophthalmol Ther
                Ophthalmol Ther
                Ophthalmology and Therapy
                Springer Healthcare (Cheshire )
                2193-8245
                2193-6528
                21 March 2020
                21 March 2020
                June 2020
                : 9
                : 2
                : 215-220
                Affiliations
                [1 ]GRID grid.439257.e, ISNI 0000 0000 8726 5837, Neuro Ophthalmology Department, , Moorfields Eye Hospital, ; London, UK
                [2 ]GRID grid.412563.7, ISNI 0000 0004 0376 6589, Ophthalmology Department, , University Hospitals Birmingham, ; Birmingham, UK
                [3 ]GRID grid.436283.8, ISNI 0000 0004 0612 2631, Neuro Ophthalmology Department, , National Hospital for Neurology & Neurosurgery, ; London, UK
                [4 ]Amsterdam, The Netherlands
                [5 ]GRID grid.83440.3b, ISNI 0000000121901201, Institute of Neurology, University College London, ; London, UK
                [6 ]GRID grid.83440.3b, ISNI 0000000121901201, National Institute for Health Research (NIHR) Biomedical Research Centre Based at Moorfields Eye Hospital NHS Foundation Trust, , UCL Institute of Ophthalmology, ; London, UK
                [7 ]GRID grid.6572.6, ISNI 0000 0004 1936 7486, Institute of Inflammation and Ageing, University of Birmingham, ; Birmingham, UK
                Article
                247
                10.1007/s40123-020-00247-9
                7196107
                32200476
                7c5b3fe5-a96c-44c8-99e1-e7b763b119f2
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 13 January 2020
                Categories
                Commentary
                Custom metadata
                © The Author(s) 2020

                chronic relapsing inflammatory optic neuropathy (crion),optic neuritis,patient-reported outcome measure (prom),quality of life

                Comments

                Comment on this article